Observation of the high efficiency of therapy for metastatic colorectal cancer

Today, understanding the molecular mechanisms involved in the activation of signaling pathways that initiate intracellular proliferation, adhesion, invasion, and angiogenesis has led to the design and widespread clinical introduction of targeted drugs that enhance the efficiency of treatment and minimize its toxicity for other organs and tissues. The possibility of using targeted therapy is assuming a particular importance in previously treated patients. The present-day experience with Regorafenib allows the latter to be considered as an effective agent in the treatment of patients with advanced colorectal cancer.